CombiGene AB

Equities

COMBI

SE0016101935

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 10:23:37 2024-04-29 am EDT			5-day change	1st Jan Change
3.75 ^SEK	-0.53%		+0.81%	+39.41%

Mar. 13	CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	CI
Feb. 21	Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	CI

New issue of CombiGenes, no 5 2023

November 27, 2023 at 05:31 am EST

Read CombiGene’s newsletter in English here.

Ingeneious issue no 5 2023 mobile friendly

About CombiGene

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB.

Please read Ingeneious, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Ingeneious and press releases are available at www.combigene.com

Latest news about CombiGene AB

CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	Mar. 13	CI
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	Feb. 20	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 16	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
CombiGene Taps Charles River Laboratories as Clinical Research Partner for Pain Project	Nov. 01	MT
Combigene AB Chooses Charles River as Preclinical Toxicology Partner for COZY01 Pain Project	23-10-31	CI
CombiGene, Zyneyro to Start Clinical Studies of COZY01 Targeting Shingles	23-10-26	MT
CombiGene AB and Zyneyro Choose Initial Indication in the Cozy01 Pain Project	23-10-26	CI
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	23-10-14	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
CombiGene CEO to Depart in September	23-06-30	MT
CombiGene AB Announces Chief Executive Officer Changes	23-06-30	CI
Combigene AB to Play an Integrate Part in the Development of National Infrastructure for ATMPs	23-05-24	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-17	CI
Combigene Enters into Collaboration Agreement with Zyneyro for the Development of A Unique Concept for Effective Relief of Chronic Pain	23-01-09	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Combigene AB Appoints Peter Ekolind as COO	22-09-27	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-25	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
CombiGene AB Signs Agreement with A Potential Value of USD 328.5 Million with Spark Therapeutics	22-02-21	CI
CombiGene AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-17	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-17	CI
Combigene AB Announces GMP Production of CG01 Made Available for Preclinical Studies Planned to Enable First in Human Study	22-01-17	CI
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	21-12-16	CI

Chart CombiGene AB

Duration

Period

More charts

Company Profile

Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Sector

Biotechnology & Medical Research

Calendar

2024-05-17 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COMBIGENE AB	+39.41%	6.81M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs